We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real‐world setting.
- Authors
Gkanti, Vasiliki; Dalamaga, Maria; Papadavid, Evangelia
- Abstract
Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real-world setting Another possible explanation could be due to lack of other possible treatment options for the patients with PSO and PsA who have previously received other biologic agents, as brodalumab was the last resort for bio-experienced patients. Thirteen patients (39.4%) were biologic-naïve, nine bio-experienced patients (27.3%) had been previously treated with tumor necrosis factor- (TNF- ) inhibitors, seven (21.2%) with anti-IL17 drugs and four (12.1%) with IL12/23 inhibitors.
- Subjects
PSORIATIC arthritis; PSORIASIS; CLINICAL trials
- Publication
International Journal of Dermatology, 2023, Vol 62, Issue 1, pe31
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16408